hepatic encephalopathy
Hepatology · 2011–2019
5decisions
1medicine
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| rifaximin Prevention of recurrence of hepatic encephalopathy where other treatments have failed or are contraindicated. | Jul 2019 | Not recommended | input received |
| rifaximin Prevention of hepatic encephalopathy in adult patients who have had prior episodes of hepatic encephalopathy, in combination with lactulose. | Jul 2012 | Recommended | no section in document |
| rifaximin Prevention of the recurrence of hepatic encephalopathy in adult patients who have had prior episodes of hepatic encephalopathy, in combination with lactulose. | Jul 2012 | Not recommended | no section in document |
| rifaximin prevention of hepatic encephalopathy (HE) in adult patients who have had prior episodes of HE, in combination with lactulose if tolerated | Nov 2012 | Deferred | no section in document |
| rifaximin prevention of the recurrence or relapse in a patient who has already had an episode of hepatic encephalopathy (HE) | Nov 2011 | Not recommended | unclear |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.